Spatial distribution of tumor vaccine improves efficacy

Laryngoscope

Volumn 113, Issue 8, 2003, Pages 1401-1405

  Couch, Marion ^a   Saunders, John K ^a   O'Malley Jr , Bert W ^b   Pardoll, Drew ^a   Jaffee, Elizabeth ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; Granulocyte macrophage colony stimulating factor; Tumor vaccine

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETROVIRUS VECTOR; TUMOR VACCINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE THERAPY; GENETIC ENGINEERING; HINDLIMB; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; IRRADIATION; LYMPH NODE; MEDICAL ASSESSMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR GROWTH; VACCINATION;

ANIMALS; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INJECTIONS; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0043125613     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-200308000-00026     Document Type: Article

References (15)

1. Couch M, Saunders JK, O'Malley BW, Pardoll D, Jaffee E. Genetically engineered tumor cell vaccine in a head neck cancer model. Laryngoscope 2003;113(3):552-556.
2. O'Malley BW, Cope KA, Johnson CS, Schwartz MR. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997;123:20-24.
3. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-3543.
4. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol 1999;17:1047-1060.
5. Borrello I, Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 2002;13:185-193.
6. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-1702.
7. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002;2:227-238.
8. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296.
9. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-2368.
10. Gastman BR, Atarshi Y, Reichert TE, et al. Fas ligand is expressed on human squamous cell carcinoma of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999;59:5356-5364.
11. Saito T, Dworacki G, Gooding W, Johnson JT, Whiteside TL. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 1999;5:1263-1273.
12. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
13. Azuma M, Ito D, Yagita H, et al. B7 antigen is a second ligand for CTLA-4 and CD28. Nature 1993;366:76-79.
14. Strome SE, Voss S, Wilcox R, et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res 2002;62:1884-1889.
15. Jaffee EM, Thomas MC, Huang AY, Hauda KM, Levitsky HI, Pardoll DM. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother 1996;19:176-183.